Contract Paperwork Gets Three More Years: Yawn-Worthy Renewal

2026-16681, Submission for OMB Review; Prohibition on Contracting With Entities Using Certain Telecommunications and Video Surveillance Services or Equipment

Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division has submitted to OMB a request to review and approve an extension of a previously approved information collection requirement regarding the prohibition on contracting with entities using certain telecommunications and video surveillance services.

2026-16679, Submission for OMB Review; Architect-Engineer Qualifications (SF-330)

The government is asking to keep using a form called SF-330, which architects and engineers fill out to show they’re qualified for big projects over a certain dollar amount. This form helps officials pick the best team for the job. If you’re an architect-engineer firm, keep an eye out—comments on this must be sent by September 14, 2026, but there’s no new cost or big changes coming.

2026-16678, Submission for OMB Review; Contract Financing

The government is asking for approval to keep collecting info from contractors about how they want to get paid during contracts. This affects companies working with the government, who must share details about payment schedules and amounts. Comments are open until September 14, 2026, so now’s the time to speak up if you have thoughts!

2026-16680, Submission for OMB Review; Privacy Training

Under the provisions of the Paperwork Reduction Act, the Regulatory Secretariat Division has submitted to OMB a request to review and approve an extension of a previously approved information collection requirement regarding privacy training.

2026-16677, Submission for OMB Review; Prospective Subcontractor Requests for Bonds

The government is asking to keep collecting info from subcontractors who want to see payment bonds before working on federal construction projects. This helps protect everyone by making sure payments are secure. If you’re a subcontractor or supplier, you might need to request these bonds soon, and comments on this process are open until September 14, 2026.

2026-16612, Regulatory Agenda

This agenda provides summary descriptions of regulations being developed by the Federal Acquisition Regulatory Council in compliance with Executive Order 12866 "Regulatory Planning and Review, as reaffirmed and amended in Executive Order 13563, "Improving Regulation and Regulatory Review." This agenda is being published to allow interested people an opportunity to participate in the rulemaking process. Additionally, members of the public can track the progress of any open and pending Federal Acquisition Regulation (FAR) rule via the "Open FAR Cases" report, which is publicly available at https://www.acq.osd.mil/dpap/ dars/farcasestatus.html. The Regulatory Secretariat Division has attempted to list all regulations pending at the time of publication, except for minor and routine or repetitive actions; however, unanticipated requirements may result in the issuance of regulations that are not included in this agenda. There is no legal significance to the omission of an item from this listing. Also, the dates shown for the steps of each action are estimated and are not commitments to act on or by the dates shown. Published proposed rules may be reviewed in their entirety at the Government's rulemaking website at https://www.regulations.gov.

Previous: 2025-04017, 60-Day Notice for the “ArtsHERE Grant Program Forms” Proposed Collection; Comment Request

The National Endowment for the Arts wants your thoughts on updating the forms for the ArtsHERE grant program. This helps make sure the paperwork is easy, clear, and not too time-consuming for artists and groups applying for grants. If you’re involved in arts grants, now’s the time to share your feedback before changes are finalized!

Next: 2025-04020, Determination That RIOMET (Metformin Hydrochloride) Oral Solution, 500 Milligrams/5 Milliliters Has Not Been Withdrawn From Sale for Reasons of Safety or Effectiveness

The FDA says RIOMET oral solution (metformin) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules. Patients and drug makers can keep counting on this medicine without any sudden changes or costs.